Luis M. Ruilope

TL;DR: The data of the paper indicate that sacubitril/valsartan improves the prognosis of hypertensive patients through an improvement in the heart and big arteries, which could provide a therapeutic advantage.

TL;DR: Overall, patients with lower baseline office SBP quartile and greater declines from baseline in SBP were associated with better cardiorenal outcomes, and the risk of primary kidney and key secondary cardiovascular composite outcomes was consistently reduced with finerenone versus placebo irrespective of baseline officeSBP quartiles.

TL;DR: El empleo de aparatos automatizados de medida de PA en consulta, como el BPTru ®, puede colaborar a disminuir el EBB y mejorar the precision of the medida of the PA en consulteda.

TL;DR: The coincidence of renal and cardiovascular damage strengthens the need for therapies attempting the simultaneous protection of both the kidney and the cardiovascular system.

TL;DR: ARB had a favorable impact on BP and renal parameters such as proteinuria with monotherapy as well as with combination therapy, highlighting their potential benefits in patients with hypertension and CKD.